Sirtuin 1 deficiency mediates chronic kidney disease-induced inflammaging cardiovascular calcification.
Chronic kidney disease (CKD) markedly accelerates calcific aortic valve disease (CAVD), yet the underlying mechanisms and therapeutic targets remain poorly defined. Modulation of the SIRT1-NLRP3 axis, particularly by semaglutide, may represent a promising strategy for preventing valve calcification.
Chronic kidney disease (CKD) markedly accelerates calcific aortic valve disease (CAVD), yet the underlying mechanisms and therapeutic targets remain poorly defined. Modulation of the SIRT1-NLRP3 axis, particularly by semaglutide, may represent a promising strategy for preventing valve calcification.
What the study was
- Study design
- Preclinical study
- Category
- Prevention
- Maturity
- Exploratory
- Journal
- Molecular biomedicine
Why it surfaced
Relevant Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk study (promising preliminary signal) meets standard-priority threshold.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.